Insights
Manufacturers
Cell and gene therapies are currently at the forefront of scientific innovation. They hold great promise for patients suffering from a range of serious ailments.
The Canadian environment is a key opportunity for pharmaceutical manufacturers to launch therapies. This article considers the various stakeholders and elements that need to be considered when launching a specialty medication in Canada.
Innomar Strategies explores digital innovation in patient support, highlighting how technology enhances enrolment, adherence, and the specialty therapy
Explore how Innomar Strategies uses physician relationships to co-create patient support programs that improve access, adherence, and therapy outcomes.
Innomar Strategies shares strategies for optimizing patient support programs to measurably improve therapy adherence and outcomes for specialty care patients.
Uncover growth opportunities in niche Canadian pharma markets. Innomar Strategies shares strategic insights to help specialty pharma brands expand their reach.
